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http://www.biomedcentral.com/1741-7007/12/64RESEARCH ARTICLE Open AccessGenome-wide screening identifies new genes
required for stress-induced phase 2 detoxification
gene expression in animals
Helen M Crook-McMahon†, Monika Oláhová†, Emma L Button†, Johnathan J Winter and Elizabeth A Veal*Abstract
Background: Phase 2 detoxification enzymes provide a vital defence against reactive oxygen species, including
xenobiotic metabolites, which cause the oxidative damage involved in drug toxicity and many diseases. Hence,
there is great interest in understanding how levels of these enzymes are regulated. CnC transcription factors, such
as mammalian Nrf2, drive the expression of phase 2 enzymes and are activated as an important conserved
response to oxidative stress and xenobiotics. For instance, the Caenorhabditis elegans Nrf2 orthologue, SKN-1, is
activated in response to arsenite by the stress-activated p38-related kinase, PMK-1, leading to increased expression
of phase 2 enzymes. Here we have used a genome-wide screening approach to identify other C. elegans genes that
are required for stress-induced increases in phase 2 detoxification gene expression.
Results: Taking advantage of the elevated phase 2 gene expression in a mutant lacking the peroxidase PRDX-2, we
have identified many new genes that are required for stress-induced expression of gcs-1, a phase 2 enzyme critically
required for glutathione synthesis. Significantly, these include genes previously implicated in resistance to ionizing
radiation, longevity and responses to pathogenic infection. Many of these new candidate activators of gcs-1 are also
required for the stress-induced intestinal expression of other phase 2 genes. However, intriguingly, our data suggest
other factors may be specifically required for the stress-induced expression of gcs-1. Notably, we demonstrate that
the candidate activator TIR-1(SARM1) and the MAPKKK NSY-1(Ask1) are required for the arsenite-induced activation
of PMK-1. However, our data suggest that the majority of candidates participate in novel mechanisms to promote
gcs-1 expression. For example, the E4 ubiquitin ligase UFD-2(UBE4B) is dispensable for PMK-1 activation but
important for maintaining nuclear levels of SKN-1, the stress-induced expression of multiple SKN-1-target
genes and oxidative stress resistance.
Conclusions: Here we present the first functional, genome-wide analysis identifying genes that are required
for activation of phase 2 detoxification genes in an animal. Our study identifies potential new regulators of
Nrf2, reveals that additional mechanisms promote the stress-induced expression of specific phase 2 detoxification
genes and provides new insight into the relationships between these universally important stress defences, oxidative
stress resistance and aging.
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Phase 2 conjugation reactions are vital for the biotrans-
formation of lipophilic molecules to more soluble, excreta-
ble substances. By counteracting reactive metabolites of
xenobiotics and oxygen (reactive oxygen species or ROS),
phase 2 reactions provide important protection against
the ROS-induced oxidative tissue damage that is associ-
ated with many diseases and aging. In addition, phase 2
reactions target diverse chemical substrates, thus present-
ing a significant barrier to both the activity and toxicity
of therapeutic drugs [1]. Phase 2 reactions are also in-
volved in the biosynthesis of hormones and inflammatory
mediators [2]. Enzymes supporting phase 2 detoxifica-
tion reactions, such as those involved in the biosyn-
thesis of glutathione (e.g., γ-glutamylcysteine synthetase
or GCS) and its conjugation to substrates (e.g., glutathione
S-transferases or GSTs), are rapidly induced following
exposure to stressful stimuli. This response is highly
conserved, reflecting the key role of phase 2 detoxification
reactions in protecting cells against ROS-induced damage.
Indeed, there is growing evidence that increased levels
of phase 2 enzymes have beneficial effects by prevent-
ing adverse drug reactions, protecting against carcino-
gens and promoting longevity [1,3,4]. On the other hand,
increased phase 2 defences can also have negative conse-
quences, for example, rendering tumour cells resistant to
treatment [5,6].
Given the medical significance of phase 2 reactions,
there is substantial interest in elucidating how these im-
portant stress and drug defences are regulated. Studies
of the mechanisms regulating inducible phase 2 gene
expression have focused upon the regulation of the Cap
and Collar (CnC) transcription factor family that is im-
portant for this induction [7,8]. CnC transcription factors,
such as Nrf2 (nuclear factor (erythroid-derived 2)-like 2)
in mammals and SKN-1 in Caenorhabditis elegans,
mediate transcriptional control of phase 2 genes. The
activity of these transcription factors is regulated at mul-
tiple levels, including transcription, translation, nuclear
localization and protein stability [7]. For example, the acti-
vation of Nrf2 in response to certain xenobiotics is medi-
ated by chemical modifications of Keap1 that prevent it
from targeting Nrf2 for degradation [5,7,9]. However, the
mechanisms by which other xenobiotics and endogenous
reactive chemicals induce the up-regulation of phase 2
genes are poorly understood.
Studies of C. elegans have provided important insight
into the regulation of phase 2 genes. SKN-1, the C. elegans
orthologue of Nrf2, activates expression of phase 2 genes,
including γ-glutamylcysteine synthetase (gcs-1), which ca-
talyses the rate-limiting step of glutathione synthesis [10].
In C. elegans, the intestine is the first line of defence
against xenobiotics. SKN-1 in the intestine is activated
in response to stress (e.g. arsenite) to increase intestinalexpression of gcs-1 and other phase 2 detoxification
genes. Several signalling pathways regulate levels of active
SKN-1. For example, phosphorylation of SKN-1 by the
stress-activated mitogen-activated protein kinase (MAPK),
PMK-1, is important for stress-induced increases in nu-
clear SKN-1 that result in increased phase 2 gene ex-
pression and oxidative stress resistance [11]. In contrast,
insulin signalling and GSK-3-mediated phosphorylation
both inhibit SKN-1 [4,12], as does interaction with the
WD40-repeat protein WDR-23 [13]. However, the iden-
tification of genes that influence gcs-1 expression by
SKN-1-independent mechanisms [14] suggests the ex-
istence of additional mechanisms for regulating phase
2 detoxification gene expression.
We have previously found that in the absence of the
2-Cys peroxiredoxin, PRDX-2, which detoxifies peroxides,
expression of phase 2 detoxification genes (e.g., gcs-1) and
resistance to arsenite-induced oxidative stress are in-
creased. For example, a stress-inducible gcs-1p::gfp tran-
scriptional reporter is expressed at significant levels in the
intestine of prdx-2 mutant C. elegans even under normal
growth conditions. Notably, this increased gcs-1 expres-
sion and arsenite resistance are only partially dependent
on SKN-1 [14]. Hence, to identify new regulators of
stress-induced phase 2 gene expression, we have con-
ducted a genome-wide RNA interference (RNAi) screen
to identify genes required for the elevated intestinal
gcs-1p::gfp expression in a prdx-2 mutant. As predicted, a
significant number of these genes are also required for the
increased intestinal expression of gcs-1p::gfp in wild-type
animals under stress conditions (arsenite exposure). Par-
tial characterization of the most robust candidates reveals
that our screen has identified new activators of PMK-1
and SKN-1, which are important for the arsenite-induced
expression of multiple phase 2 genes and arsenite resist-
ance. However, our data suggest that the majority of
candidate genes may promote arsenite-induced gcs-1
expression by alternative mechanisms, outside or down-
stream of the PMK-1/SKN-1 pathway. Indeed our study
reveals unanticipated, additional complexity in the regula-
tion of phase 2 detoxification systems and stress resistance
in animals.
Results
Genome-wide RNAi screening identifies genes regulating
gcs-1p::gfp expression
To identify new activators of phase 2 gene expression,
particularly genes that are required for the stress-induced
intestinal expression of these genes, we performed a
genome-wide RNAi screen for genes required for the
elevated intestinal expression of gcs-1p::gfp in the prdx-2
mutant background [14]. As intestinal expression of gcs-
1p::gfp was assessed in the progeny of RNAi-treated
worms (Figure 1), this prevented us from examining
prdx-2 (gk169) gcs-1p::gfp worms fed 16,255 RNAi-expressing E. coli clones in library
(1) (2)
P
‘Low’
P
Screened effect of 15,304 RNAi on intestinal GFP levels (indicated by arrows) 951 essential genes(RNAi produce emb, let or ste
phenotypes)
355 RNAi clones reduced intestinal
gcs-1p::gfp expression to undetectable levels 
in >50% animals (Fig. S2 and Table S3)
50 RNAi clones dramatically increased
intestinal gcs-1p::gfp expression in 
>50% animals (Table S2)
237 genes not previously reported 
essential in wild-type
rescreened
(3x)
‘N ’
21 genes 
required for non-
phase 2 gene: 
(F09E5.3::gfp)
(Table S3)
(i)
70 genes that are synthetic lethal 
with loss of prdx-2
(Table S1)
P
P
‘High’
one
24 genes required for
(ii)
rescreened
(3x) 
90 genes reproducibly required for 
intestinal expression of gcs-1p::gfp
P
P intestinal expression of
gst-4p::gfp (Table S3)(iii)
Secondary screen in 
wild type (3x) 
16 genes robustly required for
in prdx-2 mutant (Table S3)
(iv)
As3+-induced intestinal expression 
of gcs-1p::gfp (Table 1)
Figure 1 Results of RNAi screening. RNAi screening identified genes that are (1) synthetic lethal with prdx-2 or (2) required for stress-induced,
intestinal expression of a phase 2 detoxification transcriptional reporter gene (gcs-1p::gfp). First, 16,255 RNAi clones were screened in prdx-2 gcs-1p::
gfp background, which contains increased, detectable ‘low’ levels of intestinal GFP (indicated by arrows for representative animals and illustration) in
addition to wild-type levels of constitutive pharyngeal GFP expression (indicated with ‘P’) [14]. Of the 951 RNAi clones that produced embryonic
lethal (emb), lethal (let) or sterile (ste) phenotypes (and hence too few prdx-2 mutant progeny for gcs-1p::gfp to be scored), 237 had not
previously been reported to affect growth or reproduction in screens of wild-type animals [15]. Following re-screening of these 237 genes
three times, 70 RNAi clones repeatedly produced emb, let and/or ste phenotypes (Additional file 1: Table S1). Of the 15,304 wells containing at
least 40 viable progeny in the initial screen, 50 RNAi clones were scored that increased intestinal gcs-1p::gfp expression, such that more than 50%
of animals in the well had a ‘high’ level of gcs-1p::gfp expression throughout the intestine (see representative animal and illustration)
(Additional file 1: Table S2). Another 355 RNAi clones reduced gcs-1p::gfp expression, such that more than 50% of animals in these wells
had no detectable intestinal gcs-1p::gfp expression (‘None’; see representative animal and illustration) (Additional file 1: Table S3). These
355 RNAi clones were re-screened three times and subjected to secondary screens: (i) 21 clones were discovered to reduce the intestinal
expression of non-phase 2 gene F09E5.3::gfp [16]; (ii) 24 clones reduced intestinal gst-4p::gfp expression (Additional file 1: Table S3); (iii)
90 clones reduced gcs-1p::gfp expression in prdx-2 mutants on each of four separate occasions (Additional file 1: Table S3); and (iv) 16 of
these clones reduced arsenite-induced intestinal gcs-1p::gfp expression in wild-type worms (N2) in each of three trials but did not reduce
F09E5.3::gfp expression (Table 1). GFP, green fluorescent protein; RNAi, RNA interference.
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gfp expression. However, incidentally, this allowed the iden-
tification of 70 genes that may be specifically required for
development or reproduction in the absence of prdx-2 (see
Additional file 1: Table S1 and Additional file 2: Figure S1).
Although the purpose of this screen was to identify
genes that were required for the elevated intestinal
expression of gcs-1p::gfp in prdx-2 mutant animals, in
the course of screening, 50 RNAi clones were noted that
increased the expression of gcs-1p::gfp still further (see
Additional file 1: Table S2). These included RNAi targetinggenes encoding E01A2.1, a glutamate-cysteine ligase
regulatory subunit and WDR-23, a WD40-repeat pro-
tein that negatively regulates SKN-1 [13]. Both of these
genes were identified by previous screens for inhibitors of
phase 2 detoxification gene expression, confirming that
our screening conditions were effective at identifying reg-
ulators of gcs-1p::gfp [13,17]. RNAi targeting glutathione
synthetase (M176.2) also increased gcs-1p::gfp expression,
providing further evidence that feedback control acts
to increase GCS-1 levels when glutathione synthesis is
inhibited [17].
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genes required for resistance to ionizing radiation and
longevity
It was found that 355 RNAi clones (approximately 2.3% of
those screened) prevented intestinal gcs-1p::gfp expression
(Figure 1 and see Additional file 1: Table S3). Secondary
screens determined that 21 of these genes were also
required for the intestinal expression of a transcriptional
GFP reporter of a non-phase 2 gene, indicating a broader
role in intestinal gene expression (see Additional file 1:
Table S3). Accordingly, these genes were eliminated as
candidate phase 2 gene regulators. Importantly, this
analysis indicated that the majority of targeted genes are
not generally required for intestinal gene expression or
GFP stability.
Although the function of more than one-third of the
identified genes is unknown, bioinformatic analysis revealed
the remainder to represent a broad range of biological
processes (see Additional file 2: Figure S2). To identify
possible functional overlaps, we compared the results of
our screen with published RNAi screens of the same RNAi
library. This revealed a statistically significant overlap (P =
0.0039) between the genes we have identified and those
found to be required for resistance to ionizing radiation
(IR) (see Additional file 1: Table S4) [18]. This suggests
that the role of these particular genes in IR resistance
might be to up-regulate phase 2 detoxification gene ex-
pression to protect against free radicals that are generated
by IR. A significant overlap (P = 0.0008) was also found
between genes required for gcs-1p::gfp expression and
those required for the increased lifespan of insulin recep-
tor (daf-2) mutants (see Additional file 1: Table S4) [19].
This supports other studies that have suggested a positive
correlation between the expression of phase 2 detoxifica-
tion systems and lifespan [3,4]. Indeed, consistent with the
vital role of gcs-1 in arsenite resistance [20], six of the
seven genes required for both the longevity of daf-2 mu-
tants [19] and intestinal gcs-1p::gfp expression were im-
portant for the resistance of wild-type animals to arsenite
(Figure 2A). This suggests that, as well as the increased
lifespan, these genes may be important for the increased
stress resistance associated with reduced insulin signalling.
However, of the four genes previously identified as re-
quired for resistance to IR [18], only dnj-22 was also
important for arsenite resistance (Figure 2A) and cand-1
RNAi actually increased arsenite resistance (Figure 2A).
This suggests that alternative mechanisms to promote
stress resistance can compensate for the reduced induc-
tion of gcs-1.
Identification of new genes required for arsenite-induced
gcs-1 expression and resistance to arsenite
Next we examined whether candidate regulators of gcs-1
affected the expression of a second phase 2 transcriptionalreporter gene, gst-4p::gfp, which is detectably expressed in
the hypodermis/body wall muscle and intestine of wild-
type animals under normal conditions [21]. Strikingly, of
the 355 RNAi clones initially identified, only 24 reduced
the intestinal level of gst-4p::gfp expression (see Additional
file 1: Table S3). This provided further corroboration that
genes identified by our screen are not generally required
for intestinal gene expression or GFP stability. However,
quantitative analysis of a subset of 24 candidates, identi-
fied 13 additional clones that significantly reduced intes-
tinal gst-4p::gfp expression in prdx-2 mutant animals (see
Additional file 2: Figure S3). This suggests that approxi-
mately half of the genes identified as important for intes-
tinal expression of gcs-1, might also be important for the
elevated expression of other phase 2 genes in animals
lacking PRDX-2. Notably, none of these RNAi clones
prevented pharyngeal gcs-1p::gfp or hypodermal gst-4p::gfp
expression. Although the effectiveness of RNAi may be
reduced in the pharynx, this suggests that they are not re-
quired for housekeeping levels of phase 2 gene expression
in other tissues.
Although identified RNAi clones were likely to include
any that can rescue the defects of the prdx-2 mutant, we
predicted our screen to have also identified genes re-
quired for the increased intestinal expression of phase 2
detoxification genes under stress conditions, here mim-
icked by loss of the peroxidase PRDX-2 [14]. To test this
hypothesis, we examined whether candidate genes were
also required for the arsenite-induced expression of gcs-
1p::gfp in wild-type animals. Although high throughput
RNAi screens for C. elegans have intrinsically high false
negative rates [22], we reasoned that less reproducible
effects were also likely to indicate RNAi clones with
more marginal effects on intestinal gcs-1p::gfp. Hence,
we chose the 90 most robust RNAi clones that ablated
intestinal gcs-1p::gfp expression in prdx-2 mutants in
each of four separate screenings (see Additional file 1:
Table S3). Importantly, the reproducibility of these
clones also indicates that the RNAi treatment was
consistently effective. Excitingly, more than half of these
RNAi clones (53) prevented arsenite-induced, intestinal
gcs-1p::gfp expression in at least one of three trials, indi-
cating that our screen had successfully identified new
candidate activators of arsenite-induced phase 2 gene
expression (see Additional file 1: Table S5). As the most
robust of these candidates, the 16 RNAi clones that pre-
vented arsenite-induced, intestinal gcs-1p::gfp expression
in each of three trials, were selected for further analysis
(Figure 1 and Table 1).
First, we examined whether these 16 potential new ac-
tivators of arsenite-induced gcs-1 expression were required
for arsenite-induced increases in endogenous gcs-1 expres-
sion. Analysis of the gcs-1p::gfp reporter line suggests
that the constitutive, pharyngeal expression, which is
Aca
nd
-1
dn
j-2
2
m
yo
-
3
B0
41
6.
5
le
t-6
53
e
lo
-5
sd
c-
2
T1
9B
10
.
2
m
dh
-
1
C2
9F
9.
1
R1
2B
2.
6
IR 
resistance
Longevity of 
daf-2 mutant
%
 
ch
an
ge
  i
n 
m
ea
n 
ar
se
ni
te
su
rv
iva
l t
im
e 
o
f  
RN
Ai
-
tre
at
ed
 a
ni
m
al
s 
co
m
pa
re
d 
wi
th
 
ve
ct
or
 c
on
tro
l
-90
-80
-70
-60
-50
-40
-30
-20
-10
0
10
20
***
***
***
***
**
*
***
*
B
-1
-0.8
-0.6
-0.4
-0.2
0
0.2
0.4
0.6
0.8
1
gs
t-7
 m
R
NA
 
le
ve
ls
 
in
 
As
3+
-
tre
a
te
d 
a
n
im
a
ls
 
re
la
tiv
e 
to
 
ve
ct
o
r c
o
n
tro
l
C1
7G
10
.1
m
th
f-1
th
oc
-
2
K0
4G
7.
11
cs
n -
2
u
fd
-2
tir
-
1
F2
2F
7.
4
ap
b-
3
dp
y-
22
sr
m
-
1
ca
n
d -
1
*
*
***
*
*
*
***
gcs-1 mRNA
gst-7 mRNA
arsenite resistance
C
-50
-40
-30
-20
-10
0
10
20
30
%
 
ch
an
ge
  i
n 
m
ea
n 
ar
se
n
ite
su
rv
iva
l t
im
e 
o
f  
RN
Ai
-
tre
at
ed
 a
ni
m
al
s 
co
m
pa
re
d 
wi
th
 
ve
ct
or
 c
on
tro
l
**
**
*
***
C1
7G
10
.1
m
th
f -1
th
o
c-
2
K0
4G
7.
11
cs
n
-
2
u
fd
-2
tir
-
1
dp
y-
22
sr
m
-
1
hp
o -
26
ap
b-
3
F2
2F
7.
4
arsenite resistance
-1
-0.8
-0.6
-0.4
-0.2
0
0.2
0.4
0.6
0.8
1
gc
s-
1 
m
RN
A 
le
ve
ls
 
in
 A
s3
+ -
tre
at
ed
 a
ni
m
al
s 
re
la
tiv
e 
to
 
ve
ct
or
 
co
n
tro
l
**
***
*
* **
**
*
C1
7G
10
.1
m
th
f-1
th
oc
-
2
K0
4G
7.
11
cs
n-
2
u
fd
-2
tir
-
1
F2
2F
7.
4
ap
b-
3
dp
y-
22
sr
m
-
1
ca
nd
-1
Figure 2 Effect of selected candidate genes on arsenite-induced gene expression and arsenite resistance. (A) The effect of selected
RNAi targeting of genes required for resistance to ionizing radiation (IR) [18] or the extended lifespan of daf-2 mutant [19] on arsenite resistance.
(B) Twelve of the most robust regulators (Table 1) on arsenite-induced expression of gcs-1 (upper panel) and gst-7 (lower panel) and (C) arsenite
resistance. In (A) and (C), comparisons are shown between the mean survival time following exposure of wild-type animals treated with the
indicated RNAi or empty vector control to 7.5 mM arsenite. Mean survival times were calculated relative to control based on data obtained from
a minimum of three separate experiments (see Additional file 2: Figure S4 for representative experiments). Error bars represent the standard error
of the mean. Statistically significant differences between the survival of RNAi-treated and control animals (*P ≤ 0.05; **P ≤ 0.01; ***P ≤ 0.001) were
identified by Cox’s regression analysis of the data obtained in all the experiments. In (B), comparisons are shown between the levels of gcs-1
(upper panel) or gst-7 (lower panel) mRNA in wild-type animals treated with the indicated RNAi or empty vector control following exposure to
5 mM arsenite for 30 min. Mean RNA levels relative to control were calculated from a minimum of three separate experiments. Error bars represent
the standard error of the mean. Statistically significant differences between the gcs-1 and/or gst-7 mRNA levels in RNAi-treated and control animals
(Student’s T test) are indicated (*P≤ 0.05; **P≤ 0.01; ***P≤ 0.001). IR, ionizing radiation; RNAi, RNA interference.
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http://www.biomedcentral.com/1741-7007/12/64unaffected by these clones, is likely to make a substantial
contribution to total gcs-1 mRNA levels. Nevertheless, the
increased intestinal expression of gcs-1 following arsenite
treatment is reflected in an approximately 2.5-fold in-
crease in total gcs-1 mRNA [8]. Hence, we examined
whether RNAi clones targeting a subset of 12 genes, rep-
resentative of each functional category (Table 1), affected
the total levels of gcs-1 mRNA in arsenite-treated animals.
These RNAi clones all reduced total gcs-1 mRNA levels inarsenite-treated wild-type animals, with seven out of
twelve clones producing a statistically significant decrease.
In many cases, gcs-1 mRNA levels were reduced to 40% to
50% of vector control levels, approximating gcs-1 mRNA
levels in untreated animals and thus indicating that induc-
tion by arsenite was greatly impaired (Figure 2B upper
panel). Thus mRNA analysis is consistent with the
reporter screens, strongly suggesting that the majority of
genes in Table 1 are important for the arsenite-induced
Table 1 Activators of stress-induced gcs-1p::gfp expression and their effects on stress-induced phase 2 gene expression, stress resistance, PMK-1 and SKN-1
Functional classification of gene targeted by RNAi Intestinal gst-4p::gfp expression mRNA (Figure 2B) Arsenite
resistance
PMK-1
activation
Nuclear levels of
SKN-1S393A::GFP
WT (N2) (Additional
file 1: Table S3)
prdx-2 (Additional
file 2: Figure S3)
gcs-1 gst-7 (Figure 2C) (Figure 4) (Figure 6A)
Gene expression Human orthologue Proposed function
C17G10.1 OGFOD1 Regulates translation - - ↓ - - ↑ -
C35C5.1 sdc-2 GOLGA6L5 Sex determination/dosage compensation ↓ ND ND ND ↓*** ↑ -
F47A4.2 dpy-22 MED12 Mediator subunit - - ↓* ↓ - ↑ -
C16A3.8 thoc-2 THOC2 Transcriptional elongation - ↓*** ↓*** ↓* ↓** ↑ ↓***
K04G7.11 SYF2 Pre-mRNA-splicing factor - ↓** ↓ ↑ ↓ ↑ ↑***
Protein homeostasis
Y102A5A.1 cand-1 CAND1 Cullin-associated NEDD8-dissociated - ↓*** ↓* - ↑* ↑ -
B0025.2 csn-2 CSN2 Cop9 signalosome subunit ↑ ↓*** ↓ ↑*** ↑* - ↑***
T05H10.5 ufd-2 UBE4B E4 ubiquitin conjugating enzyme ↓ ↓*** ↓ ↓* ↓ - ↓***
Signal transduction
F13B10.1 tir-1 SARM1 Pathogen responses - ↓*** ↓ ↓* ↓*** ↓*** -
T28H11.2 srm-1 - Serpentine receptor - - ↓** - ↓ ↑ -
ZK792.3 inx-9 - Innexin - - ND ND ND ND -
Growth/metabolism
C06A8.1 mthf-1 MTHFR Methylenetetrahydrofolate reductase - ↓*** ↓** ↓* ↓ ↑ -
C34F11.3 AMPD2 AMP deaminase 2 - ↓*** ND ND ND ND -
Structural
F46E10.11 hpo-26 - Hypersensitive to pore-forming toxin - ↓*** ND ND ↓ ↑ ↑***
Transport/trafficking
R11A5.1 apb-3 AP3B1/2 Adaptin - - ↓** ↑*** - ↑ ↑***
Unknown function
F22F7.4 - - - ↓* ↓* - - -
Sixteen RNAi that prevented any detectable intestinal gcs-1p::gfp expression in prdx-2 mutant animals and in more than 50% of wild-type animals treated with 1 mM arsenite for 90 min (N2 gcs-1p::gfp) on each of three
occasions on which they were screened, following quantitative analysis, but which did not reduce intestinal expression of a non-phase 2 reporter gene, F09E5.3::gfp (Additional file 1: Table S3). These genes were placed
into categories based on gene ontology [15]. Where RNAi affected gst-4p::gfp expression in wild-type (Additional file 1: Table S3) or prdx-2 mutant animals (Additional file 2: Figure S3) the effect is indicated by an
arrow. Where RNAi produced a greater than 10% change in gcs-1 or gst-7 mRNA levels in arsenite-treated animals (Figure 2B), arsenite resistance (Figure 2A,C), PMK-1 phosphorylation in arsenite-treated animals
(Figure 4) or levels of SKN-1S393A::GFP in intestinal nuclei (Figure 6A) this is indicated. Statistically significant differences from control animals are indicated (*P < 0.05; **P < 0.01; ***P < 0.001). ND, not determined; RNAi,
RNA interference; WT, wild type.
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http://www.biomedcentral.com/1741-7007/12/64expression of gcs-1 (Figure 2B upper panel). Notably, only
ten of these sixteen RNAi’s reduced the intestinal expres-
sion of gst-4p::gfp in either wild-type or prdx-2 mutant an-
imals (Table 1, Additional file 1: Table S3 and Additional
file 2: Figure S3). Hence, to further test the generality of
the role of candidate genes in phase 2 gene expression, we
investigated whether the subset of 12 RNAi affected the
arsenite-induced expression of another phase 2 gene, gst-
7, which is also induced two- to threefold by arsenite [8].
This revealed that RNAi targeting five of these genes (tir-
1, ufd-2, thoc-2, mthf-1 and F22F7.4) significantly reduced
gst-7 mRNA levels in arsenite-treated animals (Figure 2B
lower panel). However, RNAi targeting of other candidate
genes either had little effect, or in two cases, csn-2 and
apb-3, actually significantly increased gst-7 mRNA levels
(Figure 2B lower panel). Together with our reporter
analysis (Table 1, see Additional file 2: Figure S3), this
suggests that while some genes are more broadly required
for stress-induced phase 2 detoxification gene expression,
others may be specifically required for the stress-induced
expression of gcs-1 (Figure 2B,C).
Next we examined whether these 12 genes were import-
ant for arsenite resistance. Notably, RNAi targeting of four
genes (sdc-2, thoc-2, K04G7.11 and tir-1) significantly
increased the sensitivity to arsenite toxicity (Figure 2A,C
and see Additional file 2: Figure S4). However, in most
cases arsenite resistance was unaffected or only slightly
reduced (Figure 2C). Moreover, similar to cand-1 RNAi
(Figure 2A), RNAi targeting of a second regulator of pro-
tein homeostasis, csn-2, actually increased arsenite resist-
ance (Figure 2C). This contrasted with the effects of other
RNAi clones identified by our screen, but was consistent
with the increased intestinal gst-4p::gfp and gst-7 mRNA
levels observed in csn-2 RNAi-treated animals (Table 1
and see Additional file 1: Table S3) and the previously
reported role of CSN-2 in regulation of phase 2 detoxifi-
cation genes and peroxide resistance [17]. CSN-2 is a
component of the Cop9 signalosome (CSN), which, as a
multisubunit complex, influences protein turnover by
removing the ubiquitin-like modifier NEDD8 from
Cullin-Ring ubiquitin ligases [23]. In agreement with
these previous studies, our data suggest that CSN-2, and
other CSN subunits, suppress basal phase 2 gene expres-
sion under normal growth conditions (Table 1) but are
required for stress-induced increases in gcs-1 expression
(e.g., arsenite or loss of prdx-2) (Table 1, Figure 3A,B).
Notably, although gcs-1 induction is impaired in CSN-
deficient animals (Figures 3A,B, 2B upper panel), the high
basal gcs-1 expression and increased expression of other
phase 2 detoxification genes, e.g., gst-7 (Figure 2B lower
panel, see Additional file 2: Figure S5), is sufficient to con-
fer increased oxidative stress resistance (Figures 2C and
3C) [17]. This suggests that for survival following expos-
ure to an acutely toxic level of arsenite, basal levels ofphase 2 detoxification gene expression may be more
important than the ability to induce gcs-1 (Figure 2). Strik-
ingly, despite their increased resistance to acute oxidative
stress, under normal growth conditions CSN-deficient
animals were short-lived (Figure 3D).
The role of genes required for arsenite-induced gcs-1p::
gfp expression in arsenite-induced activation of PMK-1
Having established that candidate genes were required
for arsenite-induced gcs-1 expression (Figure 2B upper
panel and see Additional file 1: Table S3) but had differ-
ent effects on the arsenite-induced expression of other
phase 2 genes (Figure 2B lower panel and see Additional
file 2: Figure S3) and/or arsenite resistance (Figure 2A,C),
we proceeded to investigate the mechanisms by which se-
lected candidate genes (Table 1) promoted stress-induced
gcs-1 expression. First, we examined whether these genes
contributed to known mechanisms involved in arsenite-
induced phase 2 gene expression. An important response
to arsenite is the activation of PMK-1 by SEK-1-mediated
phosphorylation. Following activation, PMK-1 phosphory-
lates SKN-1 increasing nuclear SKN-1 levels and promot-
ing gcs-1 expression [11]. Hence, we tested whether genes
required for arsenite-induced activation of gcs-1p::gfp
(Table 1) were required for PMK-1 activation. Strikingly,
only RNAi targeting the Toll/interleukin-1 receptor do-
main protein, TIR-1, reduced the arsenite-induced activa-
tion of PMK-1 (Figure 4). This suggests that the other
genes are required for alternative, PMK-1-independent,
mechanisms to activate gcs-1p::gfp. Indeed, there was even
an indication that many RNAi clones caused an increase
in PMK-1 phosphorylation, perhaps reflecting a compen-
satory activation of PMK-1 when other signalling path-
ways are disrupted (Figure 4).
TIR-1 and NSY-1 are required for arsenite-induced
activation of the p38-related MAPK, PMK-1
Previous studies have shown that TIR-1 and the MAPKKK
NSY-1 are both required for the activation of PMK-1 in
response to pathogenic infection but not for responses
to arsenite [11,24,25]. Hence, to confirm our RNAi data
suggesting that TIR-1 is required for arsenite-induced ac-
tivation of PMK-1 (Figure 4), we examined the phosphor-
ylation of PMK-1 in wild-type, tir-1 and nsy-1 mutant
C. elegans. Consistent with previous studies, treatment
of wild-type animals with 5 mM arsenite caused a rapid
increase in the level of PMK-1 phosphorylation that was
maximal by 5 min (Figure 5A) [14]. In contrast, there was
no detectable phosphorylation of PMK-1 in tir-1 or nsy-1
mutant C. elegans after 5 min arsenite treatment. This
suggests that TIR-1 and NSY-1 are both required for the
arsenite-induced activation of PMK-1. Indeed, although
nsy-1 was not identified by our initial genome-wide
screen, both tir-1 and nsy-1 RNAi significantly reduced
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Figure 3 Cop9 signalosome has multiple roles in the regulation of gcs-1p::gfp expression, arsenite resistance and longevity. csn-2, csn-4
and csn-5 RNAi significantly (A) reduce the basal and arsenite-induced intestinal expression of gcs-1p::gfp in prdx-2 mutant animals, (B) reduce
the arsenite-induced expression of gcs-1p::gfp in wild-type animals, (C) increase the arsenite resistance but (D) reduce the lifespan of wild-type
animals compared with animals maintained on empty vector control. In (A) and (B), levels of intestinal GFP were assessed under the fluorescent
stereoscope using the scoring criteria illustrated in Figure 1 and described in Methods. Statistically significant differences between RNAi-treated
samples and empty vector control are indicated. **P < 0.01; ***P < 0.001. (C) The survival on 7.5 mM arsenite and (D) lifespan of csn-2, csn-4 and
csn-5 RNAi were statistically significant from empty-vector-control-treated animals (P < 0.001 in each case). Each experiment was repeated at least
twice with similar results. GFP, green fluorescent protein; RNAi, RNA interference; WT, wild type.
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http://www.biomedcentral.com/1741-7007/12/64the level of gcs-1p::gfp induced by arsenite in wild-type
and prdx-2 mutant animals (Figure 5B). Moreover, con-
sistent with the important role of PMK-1 activation and
gcs-1 expression in resistance to arsenite [11,20], tir-1 and
nsy-1 mutant animals were significantly more sensitive to
arsenite toxicity than wild-type animals (Figure 5C). Thus,
here we have identified that TIR-1 and NSY-1, which are
required for PMK-1 activation during infection, are also
important for activation of PMK-1 in response to arsenite.
Importantly, the inability of tir-1 RNAi treatment to
increase further the arsenite-sensitivity of pmk-1 mutant
animals (Figure 5D) suggests impaired PMK-1 activation
underlies the arsenite-sensitivity of TIR-1-deficient animals
(Figure 5).Candidate RNAi that reduces levels of SKN-1 in intestinal
nuclei has broad effects on arsenite-induced phase 2
detoxification gene expression
Next, we focused on determining how other candidate
genes promoted arsenite-induced gcs-1 expression. The
arsenite-induced expression of gcs-1 is highly dependent
on the SKN-1 transcription factor [8]. Although PMK-1-
dependent phosphorylation is important for accumula-
tion of SKN-1 in intestinal nuclei, SKN-1 activity is also
regulated by other mechanisms. For instance, phosphor-
ylation of SKN-1 by GSK-3 or the insulin-regulated
AKT/SGK kinases directly inhibits SKN-1 activity [4,12].
Accordingly, we investigated whether other genes identi-
fied by our screen might be required for the activation
Figure 4 Effect of genes required for stress-induced activation of gcs-1 on arsenite-induced PMK-1 activation. Western blot analysis of
RNAi and vector-control-treated animals before and following 5 min exposure to 5 mM arsenite revealed that out of 14 of the most robust activators
of gcs-1p::gfp (Table 1), only tir-1 RNAi reduced the level of PMK-1 phosphorylation. (A) Mean percentage difference between the level of PMK-1
phosphorylation in arsenite-treated control and RNAi-treated animals following analysis of quantitative densitometry data obtained from at
least two independent experiments. ***indicates that tir-1 RNAi significantly reduced PMK-1 phosphorylation compared with vector control
(Student’s T test, P = 0.00056). The effects of other RNAi clones on arsenite-induced PMK-1 phosphorylation were not statistically significant (P > 0.05).
(B) Representative Western blots of those quantitatively analysed in (A). RNAi, RNA interference.
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http://www.biomedcentral.com/1741-7007/12/64of SKN-1 by a PMK-1-independent mechanism. As the
basal levels of SKN-1::GFP in intestinal nuclei are nor-
mally undetectably low, to test this hypothesis we examined
whether candidate genes (Table 1) affected the nuclear
abundance of a constitutively active form of SKN-1 in
which the GSK-3 phosphorylation site had been mutated;
SKN-1S393A::GFP [12]. Unexpectedly, RNAi targeting sev-
eral genes, including K04G7.11 and apb-3, substantially
increased nuclear SKN-1S393A::GFP levels (Figure 6A).Moreover, whereas wild-type SKN-1::GFP was undetectable
in the intestinal nuclei of control animals, these RNAi
clones also caused wild-type SKN-1::GFP to be detected in
the intestinal nuclei of a significant number of animals
(Figure 6B). Thus, paradoxically, loss of K04G7.11 and
apb-3 prevents arsenite-induced increases in intestinal
gcs-1p::gfp expression (Table 1) and gcs-1 mRNA levels
(Figure 2B), despite increased levels of nuclear SKN-1
(Figure 5A). This suggests both genes act downstream
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Figure 5 TIR-1 and NSY-1 are required for responses to arsenite. (A) Western blot analysis of the phosphorylation of PMK-1 in wild-type
(N2), tir-1 (tm3036), nsy-1 (ag3) and pmk-1 (km25) mutant animals before and following treatment for the indicated times with 5 mM sodium
arsenite. This revealed that TIR-1 and NSY-1 are both required for the phosphorylation of PMK-1, which occurs maximally within 5 min of arsenite
treatment. β-tubulin levels are shown as a loading control. (B) The basal and arsenite-induced intestinal expression of gcs-1p::gfp is reduced
following tir-1 and nsy-1 RNAi treatment of prdx-2 mutant and in wild-type animals treated with arsenite. *** indicates a statistically significant
difference from vector control P < 0.001; ** indicates a statistically significant difference from vector control P < 0.01 (chi2 test). (C) tir-1 (tm3036)
and nsy-1 (ag3) mutant animals are significantly more sensitive to 10 mM arsenite than wild-type (N2) (log-rank N2 vs tir-1, P < 0.001; N2 vs nsy-1,
P = 0.004). All experiments were repeated at least twice with similar results. (D) Assessment of the viability of tir-1 RNAi and vector-control-treated
wild-type and pmk-1 mutant animals on 7.5 mM arsenite revealed that tir-1 RNAi increases the arsenite-sensitivity of wild-type (N2) but not pmk-1
(km25) animals. Statistical analysis: wild-type vector vs tir-1 RNAi, P <0.001; pmk-1 vector vs tir-1 RNAi, P = 0.32; wild-type vector vs pmk-1 vector,
P < 0.001. GFP, green fluorescent protein; RNAi, RNA interference.
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http://www.biomedcentral.com/1741-7007/12/64of SKN-1, or through parallel SKN-1-independent path-
ways, to promote gcs-1 expression. Notably, apb-3 and
K04G7.11 RNAi did not prevent the arsenite-induced ex-
pression of four other phase 2 genes, gst-7, gst-4, dhs-8
and sdz-8 (Figure 2B and 6C). Indeed, consistent with the
increased levels of nuclear SKN-1, gst-7, gst-4, dhs-8 and
sdz-8 mRNA levels were even slightly increased in apb-3
and K04G7.11 RNAi-treated animals (Figure 6C). This
indicates apb-3 and K04G7.11, like csn-2, and potentially
other genes identified by our screen (Figure 6A), are not
universally important for the arsenite-induced expression
of all phase 2 genes but specifically required for arsenite-
induced increases in gcs-1mRNA expression.
Although the reductions in PMK-1 activity associated
with tir-1 RNAi (Figure 4) were insufficient to inhibit
nuclear accumulation of the hyperactive SKN-1S393AGFP
mutant (Figure 6A), excitingly, RNAi clones targeting
thoc-2 and ufd-2 significantly reduced the levels of SKN-
1S393A::GFP in intestinal nuclei, indicating that UFD-2
and THOC-2 are required for nuclear SKN-1 abundance
(Figure 6A). SKN-1 activity is essential for the C. elegans
transcriptional response to arsenite [8]. Indeed, in contrast
to apb-3 and K04G7.11, thoc-2 and ufd-2 were important,
not only for the arsenite-induced expression of gcs-1,but of several other SKN-1-regulated phase 2 genes
(Figure 6C). Indeed, ufd-2 RNAi produced a statistically
significant reduction in the total mRNA levels for all five
phase 2 genes that we investigated.
To test whether the associated reduction in SKN-1
activity could underlie the reduced arsenite-induced
phase 2 gene expression in these UFD-2-deficient ani-
mals (Figure 6C), we examined whether wdr-23 RNAi,
which increases SKN-1 activity and intestinal expression
of gcs-1p::gfp (Figure 6D) [13,26], bypassed the require-
ment for UFD-2. The inability of ufd-2 RNAi to reduce
intestinal gcs-1p::gfp expression in wdr-23 RNAi-treated
animals (Figure 6D) suggests that loss of WDR-23 in-
creases SKN-1 levels sufficiently to restore normal expres-
sion of phase 2 genes to UFD-2-deficient animals. These
data are consistent with UFD-2 promoting arsenite-
induced phase 2 gene expression and oxidative stress
resistance by increasing SKN-1 activity. Moreover, despite
normal levels of PMK-1 phosphorylation, but consistent
with the reduced SKN-1 activity and arsenite tolerance as-
sociated with ufd-2 RNAi, ufd-2 (tm1380) mutant animals
(predicted null) were also more sensitive to arsenite tox-
icity than wild-type animals (Figure 6E and see Additional
file 2: Figure S6).
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Figure 6 Activators of gcs-1 have diverse effects on SKN-1 and expression of other SKN-1 target genes. Some candidate activators act
independently or downstream from SKN-1 to increase gcs-1 expression whereas others, such as UFD-2, are required for nuclear SKN-1 levels and
arsenite-induced expression of multiple phase 2 detoxification genes. (A) The effect of 14 RNAi that reduce intestinal gcs-1p::gfp expression in
prdx-2 mutant and arsenite-treated animals (Table 1) on the levels of a constitutively active form of SKN-1 (SKN-1B/CS393A::GFP) present in intestinal
nuclei [12]. RNAi that produced a statistically significant decrease (***P < 0.001) or increase (***P < 0.001; *P < 0.05) in nuclear SKN-1 levels are indi-
cated. The data shown were obtained in three independent experiments. (B) K04G7.11 and apb-3 RNAi significantly increased (***P < 0.001; **P < 0.01)
wild-type SKN-1::GFP forms (SKN-1op::GFP) [4] in two independent experiments (representative experiment is shown). (C) Effect of K04G7.11,
apb-3, ufd-2 and thoc-2 RNAi, compared with vector control, on the total gcs-1, gst-4, gst-7, dhs-8 and sdz-8 mRNA levels in animals treated for
30 min with 5 mM sodium arsenite. (D) wdr-23 RNAi causes a similar increase in intestinal expression of gcs-1p::gfp in vector control and ufd-2
RNAi-treated animals. The data shown were obtained in two independent experiments. (E) The survival of L4-larval-stage wild-type and ufd-2
(tm1380) mutant animals on plates containing 7.5 mM sodium arsenite (As3+) was monitored with log-rank analysis indicating that ufd-2
(tm1380) mutant animals are significantly more sensitive to the toxicity of arsenite than wild type (N2) (P < 0.001 in each case). n = 30 to 36.
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Conserved MAPK (p38 and PMK-1) and CnC transcrip-
tion factors (Nrf2 and SKN-1) are vital for stress-induced
increases in phase 2 detoxification gene expression and
accordingly protect both normal and tumour cells fromxenobiotic/drug-induced oxidative damage. Although work
has focused on the regulation of p38 (PMK-1)/Nrf2 (SKN-1)
activity, here we provide evidence that the regulation of
stress-induced increases in phase 2 gene expression in ani-
mals is much more complex than previously appreciated.
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Figure 7 Proposed model indicating the different roles of
candidate activators in the activation of phase 2 detoxification
gene expression. TIR-1, NSY-1, THOC-2, UFD-2, K04G7.11, APB-3 and
CSN-2 participate in the activation of phase 2 detoxification gene
expression and oxidative stress resistance. In C. elegans the
SKN-1 transcription factor is essential for phase 2 detoxification
gene expression and oxidative stress resistance. Levels of SKN-1 in
intestinal nuclei are normally low due to inhibitory phosphorylation
by (a) GSK-3 (serine 393) [12] and (b) insulin-regulated kinases [4]
and (c) interaction with WDR-23, which inhibits DNA binding
[13,26]. Oxidative stress increases the phosphorylation of the
PMK-1 MAPK. Active PMK-1 phosphorylates SKN-1, increasing
levels of SKN-1 in intestinal nuclei, phase 2 gene expression and
oxidative stress resistance [11]. Our data suggest that TIR-1 and
NSY-1 are important for arsenite-induced activation of PMK-1 but
that THOC-2 and UFD-2 act downstream of PMK-1 to promote
SKN-1 activity by unidentified mechanism(s). Intriguingly, our data
suggest that several candidates identified by our screen, including
APB-3, CSN-2 and K04G7.11, may be dispensable for the expression
of other phase 2 detoxification genes but act to increase expression
of gcs-1 via unidentified mechanisms downstream or independently
from PMK-1 and SKN-1. We suggest that the increased nuclear
levels of SKN-1 in apb-3, csn-2 and K04G7.11 RNAi-treated animals,
which have lower arsenite-induced gcs-1 expression (Figure 2B and 6C),
could indicate that glutathione contributes to a feedback mechanism
to inhibit SKN-1 (as indicated by ?). ROS, reactive oxygen species.
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http://www.biomedcentral.com/1741-7007/12/64Our RNAi screening in C. elegans has uncovered new
genes that are required for the elevated expression of a
phase 2 detoxification gene (gcs-1) under stress conditions
(Table 1 and see Additional file 1: Table S3). Partial
characterization of some of the most robust candidate
genes has identified new genes required for the arsenite-
induced activation of PMK-1 and SKN-1. However, des-
pite PMK-1's critical role in promoting arsenite-induced
gene expression [8,11], our data suggest that many of
these new activators of gcs-1 expression participate in
novel mechanisms to promote phase 2 gene expression
that are downstream or independent of PMK-1 (Figure 7).
For example, UFD-2 is required for SKN-1 activity but
not PMK-1 activation (Figures 4B, and 6, see Additional
file 2: Figure S6). Moreover, our screening has revealed
genes, such as mthf-1 and F22F7.4, that are important for
arsenite-induced increases in the expression of multiple
phase 2 genes without apparently affecting either PMK-1
or SKN-1 activity. This raises the intriguing possibility
that a significant number of genes identified here may
contribute to the stress-induced activation of phase 2
genes by mechanisms outside of the canonical PMK-1/
SKN-1 pathway.
Identification of new genes required for the activation of
specific or multiple phase 2 genes
SKN-1 is generally important for the stress-induced ex-
pression of multiple phase 2 genes. Consistent with this,
the new activators of PMK-1 and SKN-1 that we have
identified, are important for the activation of multiple
phase 2 genes (Table 1 and Figure 6). Indeed, like SKN-1
[8], UFD-2 is also required for intestinal gst-4 expression
under non-stress conditions (Table 1 and Additional
file 2: Table S3). However, our data suggest that many
of the genes identified here may be specifically important
for the stress-induced expression of gcs-1 (Figures 2B
and 6C, and Table 1 and see Additional file 2: Figure S3).
Studies of yeast have revealed that transcriptional
responses to oxidative stress involve the activation of
parallel signalling pathways and transcription factors to
coordinate the expression of distinct and overlapping sets
of phase 2 genes [27]. Excitingly, our data suggest that al-
ternative pathways, involving some of the genes identified
here, may also contribute to the regulation of different
subsets of phase 2 genes in animals. For instance, unex-
pectedly, we have identified several genes (e.g., apb-3
and csn-2) that are required for stress-induced increases
in gcs-1 even in the presence of high levels of nuclear
SKN-1. This suggests that arsenite-induced gcs-1 ex-
pression also involves other regulators acting down-
stream of PMK-1 to promote SKN-1 activity specifically at
this promoter. In addition to participating in the glu-
tathionylation of toxic electrophiles, glutathione has a key
role as a cell redox buffer. Hence, the presence of theseadditional regulatory mechanisms may be important
for allowing gcs-1 expression and glutathione biosyn-
thesis to be regulated independently from other phase
2 genes (Figure 7).
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http://www.biomedcentral.com/1741-7007/12/64High basal levels of phase 2 detoxification gene
expression protect against acute stress conditions but do
not necessarily extend lifespan
RNAi targeting subunits of the CSN increase the expres-
sion of phase 2 reporter genes in wild-type animals [17].
Hence, we were surprised when our screen identified
csn-2 amongst the genes required for the elevated gcs-
1p::gfp and gst-4p::gfp expression in the prdx-2 mutant
background. However, our further analysis has revealed
that, despite high basal levels of phase 2 gene expression
and increased levels of nuclear SKN-1 (Figure 6A) [17],
CSN-deficient animals are unable to effectively increase
the expression of gcs-1 in response to arsenite (Figures 2B
upper panel and 3A,B, and Table 1). Despite this attenu-
ated response to arsenite, CSN-deficient animals are more
resistant to both arsenite (Figure 2C and 3C) and another
oxidative stress-causing agent, tert-butyl peroxide [17]. In-
deed, analysis of other genes identified here indicates that
the inability to induce gcs-1 expression (Figure 2B upper
panel), does not necessarily correlate with a lower arsenite
tolerance (Figure 2C). Accordingly, we propose that in
conditions of acute arsenite toxicity, basal levels of gcs-1
expression may be more important for survival than the
ability to increase gcs-1 mRNA levels. This suggests that
approaches to increase the basal levels of phase 2 gene
expression may be effective as a means to prevent the
acute toxicity associated with particular drugs [1].
Despite their increased oxidative stress resistance,
CSN-deficient animals are short-lived (Figure 3D). This
is consistent with increasing evidence that there is not
necessarily a direct correlation between resistance to en-
vironmental oxidative stress and longevity. For example,
prdx-2 mutant animals have high basal expression of
phase 2 detoxification genes and are more resistant to
arsenite but age prematurely and are short-lived [14]. It
is possible that the short lifespan of CSN-deficient and
PRDX-2-deficient animals reflect unrelated functions of
the CSN and PRDX-2. However, these findings do support
other studies suggesting that constitutively high levels of
phase 2 detoxification can be deleterious [4,14,28]. Thus,
although increased SKN-1 activity can extend lifespan
[4,13], the ability to regulate phase 2 detoxification gene
expression in response to changes in the environment
may also be important.
TIR-1 and NSY-1 are required for PMK-1-dependent
responses to oxidative stress and pathogens
Our analysis of the most robust regulators of gcs-1
expression identified TIR-1 as important for arsenite-
induced activation of the p38-related MAPK, PMK-1.
TIR-1 and the MAPKKK NSY-1 are required for activa-
tion of PMK-1 in response to pathogens and for the
resistance of C. elegans to infection [25]. Here we have
shown that TIR-1 is also required for the induction ofphase 2 detoxification gene expression and resistance to
the oxidative stress-causing agent, arsenite. This indi-
cates that arsenite and pathogens may activate similar
signalling pathways/defence mechanisms and raises the
intriguing possibility that the expression of phase 2 de-
toxification genes may contribute to the role of TIR-1 in
protecting against pathogenic infection. This is consist-
ent with recent studies revealing that SKN-1-dependent
expression of phase 2 detoxification genes is important
for C. elegans resistance to bacterial infection [29,30].
Identification of genes that interact with prdx-2
Our screen has also uncovered genetic interactions with
prdx-2. For instance, in the course of screening we iden-
tified 70 genes that may specifically be required for the
development or reproduction of animals lacking PRDX-2
(see Additional file 1: Table S1). Consistent with a func-
tional overlap between these genes and the peroxidase
prdx-2, functional analysis revealed that many encoded
stress defence proteins (Additional file 2: Figure S1).
Indeed, the 11 RNAi clones that produced the most
severe phenotype, preventing the survival or growth of
prdx-2 mutant C. elegans, included three targeting genes
encoding peroxide-detoxifying enzymes: two catalases
(ctl-1 and ctl-2) and the mitochondrial 2-Cys peroxire-
doxin (prdx-3). This suggests an essential role for peroxide-
detoxifying enzymes that is partially redundant with prdx-2
(see Additional file 1: Table S1).
Many of the RNAi clones that caused a reproducible
loss of intestinal gcs-1p::gfp expression in prdx-2 mutant
worms did not affect the induction of gcs-1p::gfp by arse-
nite in wild-type animals. These will include any RNAi
clones that specifically rescue the defects responsible for
the elevated intestinal gcs-1p::gfp expression in prdx-2
mutant animals or that are more specifically required
for the induction of gcs-1 in response to other stresses,
e.g., peroxide. Further studies to distinguish between these
possibilities may uncover stress-specific pathways to
up-regulate phase 2 detoxification genes. Alternatively, by
identifying genes required for Prx-specific effects on
signalling, this may improve our understanding of how
signalling functions contribute to the conserved role of
Prx in longevity [31].
Genes identified by this screen may include potential
therapeutic targets for prevention or treatment of cancer
and age-associated diseases
The important role that phase 2 detoxification enzymes
play in protecting against drug and stress-induced cell
damage has stimulated interest in developing ‘chemopre-
ventive’ agents to increase their levels and prevent
the toxic and carcinogenic effects associated with this
oxidative damage. Conversely, phase 2 detoxification en-
zymes afford tumour cells important protection against
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based drugs [5]. Our study provides important insight into
the genes and pathways involved in up-regulating one of
these enzymes in C. elegans. The conservation of stress
response pathways suggests that human orthologues of
these genes may provide new targets for approaches to
manipulate the levels of phase 2 enzymes, to either protect
cells or potentiate the toxicity of chemotherapeutic drugs.
For instance, the human orthologue of UFD-2, UBE4B,
has been proposed as a new target for chemotherapy, fol-
lowing the discovery that UBE4B promotes p53 degrad-
ation [32]. If the function of UFD-2 is conserved and
UBE4B is important for Nrf2 activity, this raises the possi-
bility that increased levels of phase 2 detoxification en-
zymes may also contribute to the survival of cancer cells
expressing high levels of UBE4B. This would also indicate
potential unwanted side effects of inhibition of UBE4B,
including increased risk of adverse drug reactions.
In addition to the implications for chemotherapeutic
interventions, our study supports the notion that the
ability to up-regulate these defences in response to stress
is important for longevity. As such it also provides new
avenues to explore in the quest to delay or prevent the
onset of age-associated diseases.
Conclusions
The regulation of the expression of phase 2 detoxification
enzymes in animals is more complex than previously
appreciated, involving both general and gene-specific
mechanisms.
Methods
Caenorhabditis elegans strains
All strains were maintained at 15°C using standard methods
[33]. N2 Bristol (wild-type), VE1: prdx-2(gk169) II, LD1172:
N2 ldIs003 [gcs-1p::gfp], VE4: prdx-2(gk169) ldIs003 [gcs-
1p::gfp] II, BC14910 dpy-5(e907)/dpy-5(e907); sEx14910
[rCesF09E5.3::GFP + pCeh361], CL2166: N2 dvIs19 [pAF15
(gst-4p::gfp-nls)] III, VE12: prdx-2(gk169) dvIs19 [pAF15
(gst-4p::gfp-nls)] III, AU3: nsy-1(ag3) II, IG685: tir-1
(tm3036) III, KU25: pmk-1(km25) IV, PP198 ufd-2(tm1380)
II, LD1257: N2 ldEx010 [SKN-1op::GFP], LD1255: N2
ldEx014 [SKN-1opS12A::GFP] and LD1252: N2 ldEx020
[SKN-1B/CS393A::GFP].
RNA interference
RNAi experiments were carried out essentially as de-
scribed previously [34]. RNAi clones were grown in Luria
Broth (LB) liquid media containing 50 μg/ml ampicillin
overnight then diluted to OD600 = 1.0 and induced with
1 mM isopropyl β-D-1-thiogalactopyranoside (IPTG).
This was used to seed plates, which were left at room
temperature for 2 days to induce double-stranded RNA
synthesis before worms were added.Genome-wide RNAi screening
Genome-wide RNAi screening was performed using a com-
mercially available RNAi feeding library (MRC Geneservice,
Cambridge, UK) [34]. Single colonies were inoculated into
800 μl of LB media containing 50 μg/ml ampicillin in 96-
well deep well plates, covered with sterile, breathable film
and incubated at 37°C on a shaking platform overnight.
Then 1 mM IPTG was added to each well and bacteria
harvested by centrifugation at 4°C, resuspended in 500 μl
LB containing 100 μg/ml ampicillin and 1 mM IPTG then
20 μl spotted onto individual wells of 24-well plates con-
taining RNAi agar. RNAi plates were incubated for 2 days
at room temperature, then approximately ten synchro-
nized L1-stage animals dispensed into each well. After
incubation at 15°C for 7 days, larval stage F1 progeny were
scored for intestinal GFP fluorescence using a Discovery
V8 Zeiss fluorescent stereomicroscope. For each batch of
RNAi clones tested, empty vector (pL4440) was included
as a negative control. Clones that gave rise to less than ap-
proximately 40 viable progeny were scored lethal or ster-
ile, as appropriate, and excluded from analysis of reporter
gene expression. Clones that affected reporter expression
were identified by comparing intestinal GFP fluorescence
with empty vector controls. All RNAi clones that reduced
intestinal gcs-1p::gfp expression to undetectable levels, i.e.
‘none’ (Figure 1), in more than 50% of the prdx-2 mutant
worms in the initial screen were re-screened three more
times and also screened three times in wild-type animals
for loss of gst-4p::gfp. For analysis of arsenite-induced
intestinal gcs-1p::gfp expression, after 7 days of incubation
on RNAi plates, worms were washed off screen plates in
M9 buffer into the corresponding well of a 24-well plate
in which the RNAi agar contained 1 mM sodium arsenite
(Sigma S-7400, Poole, UK). Worms were incubated at 15°C
for 90 min then reduced intestinal gcs-1p::gfp expression
compared with empty vector control was assessed as de-
scribed above. All RNAi clones that were analysed further
were sequenced to confirm the identity of the targeted
gene.
Comparative analysis of genes identified in different
genome-wide RNA interference screens
The statistical significance of the observed overlap between
different gene lists obtained in different genome-wide
RNAi screens was calculated using cumulative hypergeo-
metric probability [35].
Scoring of green fluorescent protein reporter gene
expression
Intestinal expression of GFP reporter genes was scored
similarly to that previously described [12]. ‘None’ indi-
cates that no GFP was detected in intestinal cells, ‘low’
indicates that GFP was detected in the nuclei of a few
(≤7) anterior or posterior intestinal cells, ‘medium’
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intestinal cells throughout the length of the intestine
and ‘high’ indicates that GFP was detected in all cells
throughout the intestine (see Figure 1 for representative
images and illustrations). For more sensitive analysis of
the effect of specific RNAi clones on intestinal GFP expres-
sion (in Table 1, Additional file 2: Figures S3 and S5 and
Figure 5), animals were mounted on an agarose pad and
scored under the 40× objective on a Zeiss Axioskop. Statis-
tically significant differences between groups (P values)
were determined using a chi2 test (Microsoft Excel).
Arsenite resistance assays
Five to ten L4-stage animals were transferred to plates
seeded with the indicated RNAi bacterial clone. Then 30
to 40 L4-stage F1 progeny of RNAi-treated animals (or
OP50-maintained N2 and ufd-2 (tm1380) mutants) were
transferred to plates containing the indicated concentra-
tion of sodium arsenite and incubated at 15°C. Viability
was assessed at the indicated time points and animals
were scored as dead and removed from the plate if
pharyngeal pumping had ceased and they did not re-
spond to gentle prodding with a platinum wire. P values
were derived from log-rank survival analyses of individ-
ual experiments (Minitable 16) or Cox’s regression ana-
lysis of multiple experiments (Figure 2).
Analysis of lifespan
To analyse lifespan, 30 L4-stage hermaphrodites were
placed onto the appropriate RNAi plate and allowed to
lay eggs. Once the eggs developed to L4 stage, approxi-
mately 150 F1 progeny were transferred to fresh RNAi
plates, so that there were 50 animals per plate. Once at
the young adult stage, animals were transferred to RNAi
plates containing 25 μM 5-fluoro-2'-deoxyuridine to pre-
vent egg laying. Animals were transferred to new RNAi
plates every few days throughout the experiment. Ani-
mals were incubated at 15°C and viability was assessed
at least every 2 days at the same time of day. Animals were
scored as dead and removed from the plate if pharyngeal
pumping had ceased and they did not respond to gentle
prodding with a platinum wire. Animals that died from
bagging, ruptured vulva or crawled off the plate were
censored. For statistical comparisons between control and
RNAi-treated animals, P values were derived from a
log-rank survival test (Minitab 16).
Immunoblotting
Approximately 3,000 synchronized L1-larval-stage wild-
type/mutant or control/RNAi-treated worms were added
to the appropriate plates and harvested at L4 larval
stage, before or following treatment with 5 mM arsenite.
As described previously [14], extracts were prepared and
equal amounts of protein (coomassie) analysed usingantibodies against the dual phosphorylated form of p38
(#9211, Cell Signaling Technology) to detect phosphory-
lated PMK-1 and anti-β-tubulin antibodies (E7, Develop-
mental Studies Hybridoma Bank, Iowa City, Iowa) as a
loading control. Quantitative densitometric analysis (area
under the peak) of Western blot autoradiographs was con-
ducted using ImageJ 1.44 to determine phosphorylated
PMK-1 levels relative to tubulin loading for each lane. The
level of phosphorylated PMK-1 in RNAi-treated or mutant
samples was then determined relative to control samples
on the same blot.
Analysis of gcs-1 and gst-7 mRNA expression
Wild-type (N2) animals were transferred to RNAi or
control plates and RNA was extracted from approxi-
mately 10,000 synchronized L3-larval-stage progeny fol-
lowing exposure to 5 mM sodium arsenite for 30 min,
which induced two- to threefold increases in gcs-1 and
gst-7 expression and 6.6-, 10.6- and 5.5-fold increases, re-
spectively, in gst-4, dhs-8 and sdz-8 mRNA levels [8]. RNA
extraction was carried out using Trizol (Sigma) and gcs-1,
gst-7, gst-4, dhs-8, sdz-8 and act-1 mRNA levels were
determined using Superscript III Platinum SYBR Green
One-Step qRT-PCR kit (Invitrogen, Paisley, UK) and Cor-
bett Life Science Rotor-Gene 6000 system. mRNA levels
were determined from a minimum of three replicate
samples relative to act-1 mRNA (For primer sequences
see Additional file 1: Table S6). These were then compared
with the levels in vector-control-treated animals. Experi-
ments were repeated at least three times and the statistical
significance of differences between gcs-1, gst-7, gst-4, dhs-
8 or sdz-8 mRNA levels in RNAi-treated and control
animals determined (Student's T test).
Additional files
Additional file 1: Table S1. Genes required for growth, development
or reproduction in the absence of prdx‐2. Table S2. RNAi clones that
increased intestinal gcs-1p::gfp expression in prdx-2 mutant. There were
50 clones that resulted in high levels of nuclear GFP throughout the
intestine of at least 50% of the RNAi-treated prdx-2 gcs-1p::gfp worms
(as illustrated in Figure 1). Table S3. RNAi clones that reduced intestinal
gcs-1p::gfp expression in genome-wide RNAi screen in prdx-2 mutants
and their effect on the expression of a non-phase 2 intestinally expressed
gene reporter F09E5.3::gfp [16] and a second phase 2 reporter gene
gst- 4p::gfp [21] in wild-type (N2) animals under normal growth conditions.
Table S4. Overlap between genes that are required for expression of
gcs-1p::gfp in the prdx-2 mutant (Table S3) and those identified by
published RNAi screens of the same RNAi library for different phenotypes.
Table S5. RNAi clones that prevented arsenite-induced intestinal gcs-1p::gfp
expression in wild-type animals. Of the 90 RNAi clones that reduced
intestinal gcs-1p::gfp expression in prdx-2 mutant animals under normal
growth conditions on each of four occasions (Table S3), 53 also prevented
an increase in intestinal gcs-1p::gfp expression in wild-type (N2 gcs-1p::gfp)
animals treated for 90 min with 1 mM arsenite. Table S6. Primer sequences
used in quantitative PCR reactions.
Additional file 2: Figure S1. Functional analysis of genes for which
RNAi produced a synthetic lethal phenotype with prdx-2 (Additional
file 1: Table S1). Figure S2. Genes required for intestinal gcs-1p::gfp
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groups. Figure S3. The role of candidate genes identified by the
screen in the regulation of gst-4p::gfp expression in prdx-2 mutant animals.
Figure S4. The effect of selected candidate RNAi (Table 1 and Figure 2B,C)
on the arsenite resistance of wild-type animals. Figure S5. Effect of csn-2,
csn-4 and csn-5 RNAi on intestinal expression of gst-4p::gfp in wild-type ani-
mals under normal growth conditions. Figure S6. UFD-2 is not required for
arsenite-induced PMK-1 phosphorylation.
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